Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus

PURPOSE: In people with type 2 diabetes mellitus (T2DM), both glucose metabolism abnormalities and atherosclerosis risk are significant concerns. This study aims to investigate the effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin (TOFO) and the dipeptidyl peptidase-4 inhibitor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomura, Shosaku, Shouzu, Akira, Taniura, Takehito, Okuda, Yoshinori, Omoto, Seitaro, Suzuki, Masahiko, Ito, Tomoki, Toyoda, Nagaoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226515/
https://www.ncbi.nlm.nih.gov/pubmed/37255963
http://dx.doi.org/10.2147/CPAA.S409786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226515/
https://www.ncbi.nlm.nih.gov/pubmed/37255963
http://dx.doi.org/10.2147/CPAA.S409786

Ejemplares similares